Efficacy of Nucleotide Analog Monotherapy and Combination Therapy with Interferon in Treating Chronic Hepatitis B

Rui YIN; Guowei MA; Wenxi YUE; Haixia GU; Ying ZHOU; Jie CHEN

Article Contents

Article Navigation > Journal of Kunming Medical University > 2025 > Accepted Manuscript

Rui YIN, Guowei MA, Wenxi YUE, Haixia GU, Ying ZHOU, Jie CHEN. Efficacy of Nucleotide Analog Monotherapy and Combination Therapy with Interferon in Treating Chronic Hepatitis B[J]. Journal of Kunming Medical University.

Citation:

PDF( 663 KB)

Efficacy of Nucleotide Analog Monotherapy and Combination Therapy with Interferon in Treating Chronic Hepatitis B

1.
School of Pharmacy，Dali University，Dali Yunnan 671000
2.
Department of Clinical Pharmacology，The Third People’s Hospital of Kunming，Kunming Yunnan 650041，China

Received Date: 2024-10-12
Available Online: 2024-12-24

Abstract

Abstract

Objective To analyze the efficacy of different nucleoside （acid） analogs （NAs） used as monotherapy and in combination with pegylated interferon α-2b （Peg-IFN-α-2b） in the treatment of chronic hepatitis B （CHB）. Methods A retrospective analysis was conducted on 229 CHB patients who visited the Hepatology Department of the Third People's Hospital of Kunming from September 2022 to August 2023. Patients were divided into six groups based on their antiviral regimen: entecavir（ETV） group （A, n = 47）, ETV combined with Peg-IFN-α-2b group （B, n = 19）, Tenofovir Alafenamide （TMF） group （C, n = 64）, TMF combined with Peg-IFN-α-2b group （D, n = 35）, Tenofovir Disoproxil Fumarate （TDF） group （E, n = 29）, and TDF combined with Peg-IFN-α-2b group （F, n = 35）. The blood routine, liver function, kidney function, HBV serological markers, and HBV-DNA levels were compared before and after 24 weeks of treatment. Results After 24 weeks of treatment, there were no statistically significant differences in efficacy rates and HBV-DNA positivity rates between the monotherapy with NAs and the combination with Peg-IFN-α-2b （P > 0.05）. Comparing before and after treatment, the ETV group had the highest effective rate, while TDF combined with Peg-IFN-α-2b group had the lowest effective rate. TDF group had the highest efficiency, while ETV combined with Peg-IFN-α-2b group had the lowest efficiency. Except for ETV+ Peg-IFN-α-2b and TDF+ Peg-IFN-α-2b groups, the HBV-DNA positivity rates in the other four groups were significantly lower after treatment compared to before（P < 0.05）. There was a significant difference in HBsAg levels among the different treatment regimens of monotherapy with NAs and combination with Peg-IFN-α-2b（P = 0.0483）. Additionally, except for the ETV and TDF groups, the serum HBsAg levels in the other four groups were significantly lower after treatment compared to before（P < 0.05）. There were no significant difference in LSM and GFR before and after treatment （P > 0.05）. In the monotherapy groups, ALT and GGT levels were significantly lower after treatment compared to before （P < 0.05）, while in the combination Peg-IFN-α-2b group, WBC, NEUT, and PLT levels were significantly lower after treatment compared to before （P < 0.05）. Conclusion Combination therapy with Peg-IFN-α-2b can reduce HBsAg levels and may be more effective in controlling the virus; however, it may cause adverse reactions such as bone marrow suppression, increasing risks. Physicians and patients need to weigh the benefits against the risks and develop personalized treatment plans based on individual circumstances.
- Chronic hepatitis B,
- Pegylated interferon α-2b,
- Tenofovir disoproxil fumarate,
- Tenofovir alafenamide,
- Entecavir

FullText(HTML)

References(40)

References

[1]	Abdulkareem L O,Ndububa D A,Uhumwangho A O,et al. Hepatitis D virus antibodies and liver function profile among patients with chronic hepatitis B infection in Abuja,Nigeria[J]. J Infect Dev Ctries,2021,15(1):141-146. doi: 10.3855/jidc.13127
[2]	高丽娟,李永库,董新颖,等. 艾米替诺福韦治疗慢性乙型肝炎患者疗效初步研究[J]. 实用肝脏病杂志,2023,26(6):789-792.
[3]	Yue T,Zhang Q,Cai T,et al. Trends in the disease burden of HBV and HCV infection in China from 1990-2019[J]. Int J Infect Dis,2022,122:476-485. doi: 10.1016/j.ijid.2022.06.017
[4]	You H,Wang F,Li T,et al. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)[J]. J Clin Transl Hepatol,2023,11(6):1425-1442.
[5]	Heimbach J K,Kulik L M,Finn R S,et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology,2018,67(1):358-380. doi: 10.1002/hep.29086
[6]	Dekker S E,Green E W,Ahn J. Treatment and prevention of acute hepatitis B virus[J]. Clin Liver Dis,2021,25(4):711-724. doi: 10.1016/j.cld.2021.06.002
[7]	Suoh M,Tamori A,Amano-teranishi Y,et al. The administration of tenofovir disoproxil fumarate for pregnant Japanese women with chronic hepatitis B[J]. Intern Med,2020,59(2):205-210. doi: 10.2169/internalmedicine.3504-19
[8]	Charlton M R,Alam A,Shukla A,et al. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia[J]. J Gastroenterol,2020,55(9):811-823. doi: 10.1007/s00535-020-01698-4
[9]	Hong X,Cai Z,Zhon F,et al. Improved pharmacokinetics of tenofovir ester prodrugs strengthened the inhibition of HBV replication and the rebalance of hepatocellular metabolism in preclinical models[J]. Front Pharmacol,2022,13:932934. doi: 10.3389/fphar.2022.932934
[10]	Liu J,Wu M,Kai J,et al. Effect of food on the pharmacokinetics of tenofovir amibufenamide: A Phase I,randomized,open-label,two-period crossover trial in healthy adult subjects[J]. Drug Des Devel Ther,2023,17:3061-3072. doi: 10.2147/DDDT.S419084
[11]	Wang X,Zhang C,Zhu Y,et al. Efficacy of 2 years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment[J]. Antiviral Res,2014,103:71-77. doi: 10.1016/j.antiviral.2014.01.009
[12]	Liu Z,Jin Q,Zhang Y,et al. 96-Week treatment of tenofovir amibufenamide and tenofovir disoproxil fumarate in chronic hepatitis B patients[J]. J Clin Transl Hepatol,2023,11(3):649-660.
[13]	Hatzakis A,Magiorkinis E,Haida C. HBV virological assessment [J]. J Hepatol,2006,44(1 Suppl): S71-S76.
[14]	Mokaya J,Maponga T G,Mcnaughton A L,et al. Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: An observational case series of South African adults[J]. J Clin Virol,2020,129:104548. doi: 10.1016/j.jcv.2020.104548
[15]	Yeh M L,Huang J F,Dai C Y,et al. Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B[J]. Expert Opin Drug Metab Toxicol,2019,15(10):779-785. doi: 10.1080/17425255.2019.1678584
[16]	Chi H,Hansen B E,Guo S,et al. Pegylated interferon alfa-2b add-on treatment in hepatitis B virus envelope antigen-positive chronic hepatitis B patients treated with nucleos(t)ide analogue: A randomized,controlled trial (PEGON)[J]. J Infect Dis,2017,215(7):1085-1093. doi: 10.1093/infdis/jix024
[17]	Gu J,Sun R,Shen S,et al. The curative effect of adefovir dipivoxil treating HBeAg negative chronic hepatitis B and treating HBeAg positive chronic hepatitis B combining interferon α-2b [J]. Pak J Pharm Sci,2015,28(4 Suppl): 1493-1497.
[18]	中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华临床感染病杂志,2022,15(6):401-427.
[19]	Zhao Q,Liu H,Tang L,et al. Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy[J]. Antiviral Res,2024,221:105782. doi: 10.1016/j.antiviral.2023.105782
[20]	Marcellin P,Wong D K,Sievert W,et al. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection[J]. Liver Int,2019,39(10):1868-1875. doi: 10.1111/liv.14155
[21]	Tricot T,Thibaut H J,Abbasi K,et al. Metabolically improved stem cell derived hepatocyte-like cells support HBV life cycle and are a promising tool for HBV studies and antiviral drug screenings[J]. Biomedicines,2022,10(2):268. doi: 10.3390/biomedicines10020268
[22]	Huang Y W,Chayama K,Tsuge M,et al. Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B[J]. Antivir Ther,2010,15(2):177-184. doi: 10.3851/IMP1508
[23]	Lau G K,Piratvisuth T,Luo K X,et al. Peginterferon Alfa-2a,lamivudine,and the combination for HBeAg-positive chronic hepatitis B[J]. N Engl J Med,2005,352(26):2682-2695. doi: 10.1056/NEJMoa043470
[24]	Huang Y W,Hsu C W,Lu S N,et al. Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B[J]. Hepatol Int,2020,14(6):997-1008. doi: 10.1007/s12072-020-10098-y
[25]	Samuel C E. Antiviral actions of interferons [J]. Clin Microbiol Rev,2001,14(4): 778-809.
[26]	Zhang M,Zhang Z,Imamura M,et al. Infection courses,virological features and IFN-α responses of HBV genotypes in cell culture and animal models[J]. J Hepatol,2021,75(6):1335-1345. doi: 10.1016/j.jhep.2021.07.030
[27]	Wang G,Guan J,Khan N U,et al. Potential capacity of interferon-α to eliminate covalently closed circular DNA (cccDNA) in hepatocytes infected with hepatitis B virus[J]. Gut Pathog,2021,13(1):22. doi: 10.1186/s13099-021-00421-9
[28]	Li M,Gao Y,Yang L,et al. Dynamic changes of cytokine profiles and virological markers during 48 weeks of entecavir treatment for HBeAg-positive chronic hepatitis B[J]. Front Immunol,2022,13:1024333. doi: 10.3389/fimmu.2022.1024333
[29]	Wu D,Wang P,Han M,et al. Sequential combination therapy with interferon,interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study[J]. Hepatol Int,2019,13(5):573-586. doi: 10.1007/s12072-019-09956-1
[30]	Lee J H,Lee Y B,Cho E J,et al. Entecavir plus pegylated interferon and sequential hepatitis B virus vaccination increases hepatitis B surface antigen seroclearance: A randomized controlled proof-of-concept study[J]. Clin Infect Dis,2021,73(9):e3308-e3316. doi: 10.1093/cid/ciaa807
[31]	Marcellin P,Ahn S H,Ma X,et al. Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B [J]. Gastroenterology,2016,150(1): 134-144. e110.
[32]	陈松海,纪冬,胡志军,等. 瞬时弹性成像联合甲胎蛋白对肝细胞癌的早期预警价值[J]. 肝脏,2019,24(1):20-23.
[33]	Głowska-Ciemny J,Szymański M,Kuszerska A,et al. The role of alpha-fetoprotein (AFP) in contemporary oncology: The path from a diagnostic biomarker to an anticancer drug[J]. Int J Mol Sci,2023,24(3):2539. doi: 10.3390/ijms24032539
[34]	钱丽媛,李长菲,罗云敬,等. 甲胎蛋白在肝癌的诊断和治疗中的研究进展[J]. 生物工程学报,2021,37(9):3042-3060.
[35]	王菡,杨江民. 甲胎蛋白含量测定的临床意义[J]. 青海医药杂志,2011,41(11):81-83.
[36]	Melani C,Dowdell K,Pittaluga S,et al. Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: An open-label,single-centre,phase 2 trial[J]. Lancet Haematol,2023,10(5):e346-e358. doi: 10.1016/S2352-3026(23)00029-7
[37]	Bazinet M,Pântea V,Placinta G,et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165,tenofovir disoproxil,and pegylated interferon alfa-2a in patients with chronic HBV infection naïve to nucleos(t)ide therapy[J]. Gastroenterology,2020,158(8):2180-2194. doi: 10.1053/j.gastro.2020.02.058
[38]	袁淳珏,潘运宝,李一荣,等. 慢性乙型肝炎与肝癌患者凝血指标的比较及其临床意义[J]. 武汉大学学报(医学版),2021,42(3):485-489.
[39]	Singh S. Medication safety in chronic kidney disease[J]. Curr Opin Nephrol Hypertens,2023,32(5):434-438. doi: 10.1097/MNH.0000000000000907
[40]	Chi X,Xiao H,Shi M,et al. Histological improvement in chronic hepatitis B patients treated with bicyclol: Real world experience[J]. BMC Gastroenterol,2019,19(1):88. doi: 10.1186/s12876-019-1005-1

Relative Articles(20)

Relative Articles

[1]	Chunyan CHEN, Zimian FAN. Correlation Analysis of Peripheral Blood SAA/CRP and NLR Levels with HBV-DNA Lload and Degree of Disease in CHB Patients. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20240522
[2]	Yingyuan ZHANG, Chunyan MOU, Huan MU, Danqing XU, Lixian CHANG, Yuanzhen WANG, Chunyun LIU, Li LIU. Comparison of Efficacy of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate on Chronic Hepatitis B. Journal of Kunming Medical University,
[3]	Li LIU, Jun-yi LI, Chun-yun LIU, Ying-rong DU, Jian-peng GAO, Hui-ming LI, Wei-kun LI, Yan-wei QI, Hui WANG. Effect of Tenofovir Combined with Ganshuang Granule on Hemodynamics of Portal Vein System in Hepatitis B Liver Cirrhosis. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20211125
[4]	Zhi-rong ZHAO, Hai-wen LI, Ni-hong LU, Ling SHEN, Xiao-fei LI, Yong-rui YANG. A Clinical Study on the Use of Propofol Tenofovir in the Treatment of Chronic Hepatitis B. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20210141
[5]	Li-xian YUAN, Hong-tao ZHANG, Rui LI, Kun-rui CHEN, Kun-qian CHEN, An-shu XU. Diagnostic Efficacy of Serum PIVKA-Ⅱ Detection in Primary Hepatocellular Carcinoma. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20201223
[6]	Xie Wei , Zhao Chuan , Wang Rong , Wang Wen Ping , Tu Hong . . Journal of Kunming Medical University,
[7]	Pu Dong , Li Xiao Fei , Yu Ting Ting , Wang Hong Ying , Zhang Run Wu , Li Li Hua , Bai Jing , Ding Cai Mei , Li Dong Ling , Yang Yong Rui . . Journal of Kunming Medical University,
[8]	Li Zhong Xi , Bai Jing Song , Tian Bo , Zhou Wen Jing , Liu Jun . . Journal of Kunming Medical University,
[9]	Zhou Ying . The Influence of GSH Combined ETV on Liver Fibrosis Indexes of Patients with CHB. Journal of Kunming Medical University,
[10]	He Min . . Journal of Kunming Medical University,
[11]	Ning Lin . . Journal of Kunming Medical University,
[12]	Liu Dong . . Journal of Kunming Medical University,
[13]	Li Hui . . Journal of Kunming Medical University,
[14]	Li Ming Ming . . Journal of Kunming Medical University,
[15]	Yang Yong Rui . . Journal of Kunming Medical University,
[16]	Yang Yong Rui . . Journal of Kunming Medical University,
[17]	An Zhi . . Journal of Kunming Medical University,
[18]	Guo Xian Li . . Journal of Kunming Medical University,
[19]	Yang Yong Rui . . Journal of Kunming Medical University,
[20]	Yang Yong Rui . The Curative Effect of Polyethylene Glycol（peg）Interferon Alpha 2a Combined with Adefovir on HbeAg Positive Chronic Hepatitis B. Journal of Kunming Medical University,